RedHill Biopharma reported $6.53M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 148.02M 59.1M Dec/2025
Cronos Group USD 927.88M 16.21M Mar/2026
RedHill Biopharma USD 6.53M 6.03M Dec/2025